OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a report released on Friday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Price Performance

Shares of NASDAQ OPGN opened at $1.23 on Friday. The business has a 50-day simple moving average of $1.02 and a two-hundred day simple moving average of $1.54. OpGen has a fifty-two week low of $0.53 and a fifty-two week high of $9.90.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.